# Elucidating the Anticancer Mechanisms of Tetrahydroxycurcumin: A Comprehensive Review of Preclinical Studies

## TL;DR

Tetrahydroxycurcumin, a derivative of curcumin, shows strong anticancer properties by targeting key cancer-related pathways and improving treatment outcomes.

## Contribution

This paper reviews the preclinical mechanisms and therapeutic potential of tetrahydroxycurcumin as a novel anticancer agent.

## Key findings

- Tetrahydroxycurcumin inhibits NF-kB and AP-1 pathways, suppressing cancer cell survival and inducing apoptosis.
- THC reduces metastasis by inhibiting matrix metalloproteinases and shows synergistic effects with traditional chemotherapeutics.
- THC has better bioavailability and stability than curcumin, addressing a major limitation in curcumin-based therapies.

## Abstract

One significant reductive metabolite of curcumin, tetrahydroxycurcumin (THC), is a promising oncology candidate because of its multifunctional bioactivities. Preclinical data indicate that THC has a strong anti‐inflammatory, antioxidant, and anticancer profile, and as such, it is a better alternative to curcumin in treatment. Mechanistically, THC regulates important transcriptional factors that are involved in tumorigenesis, specifically nuclear factor‐kappa B (NF‐kB) and activator protein‐1 (AP‐1). Uncontrolled proliferation, inflammation, and resistance to apoptosis have been linked to aberrant activation of these pathways. Inhibition of NF‐kB and AP‐1 induced by THC suppresses cancer cell survival signaling and triggers apoptotic cell death. Simultaneously, THC inhibits the action of matrix metalloproteinases (MMPs), which are involved in the degradation of extra cells and metastatic spread, and promote tumor invasion and metastasis. Experimental research has also shown the effectiveness of THC in various cancers such as breast cancer, prostate cancer, colon cancer, and skin cancer. It is important to note that THC increases the therapeutic index of traditional chemotherapeutics, where they show synergistic interactions and counteract drug resistance mechanisms, which is a key obstacle in clinical oncology. THC has better physiological stability and bioavailability compared to its parent molecule, a characteristic that alleviates one of the greatest translational limitations of curcumin. This review highlights the molecular processes underlying the anticancer action of THC, its possible use as a single agent and as an adjuvant to already established chemotherapeutic protocols, and the translational issues that need to be overcome to achieve clinical acceptance. Together, the existing evidence supports THC as an attractive future cancer therapeutic with the potential to improve treatment outcomes and overcome drug resistance.

Tetrahydroxycurcumin is an attractive multifunctional compound in cancer‐driven therapeutics. Its anticancer potential in modulating a wide range of oncogenic signaling networks, combined with its dual properties as an antioxidant and anti‐inflammatory agent, highlights its potential to become a transformative anticancer drug. One of the principal curcumin metabolites that has gained significant interest in oncological studies is tetrahydroxycurcumin (THC) due to its strong anticancer, antioxidant, and anti‐inflammatory effects. It has been shown that THC has a regulatory effect on several key signaling pathways related to cancer control, such as nuclear factor kappa B (NF‐kB), activator protein‐1 (AP‐1), and matrix metalloproteinases (MMPs). By regulating such pathways, THC stimulates apoptosis, tumor suppressor functions, and inhibits the spread of metastasis.